The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the ...
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback